
PRESS / ARTICLES
at THE ESMO 2018 Annual Meeting in munich, germany On October 22, the award for Best poster in the developmental therapeutics Category was given to the presentation of the phase i study of Pt-112 in advanced solid tumors, with Poster #437P, “PT-112: A well-tolerated novel immunogenic cell death (ICD) inducer with activity in advanced solid tumors.”
Click Here to Access The abstract
Phosplatin Therapeutics Presents Poster revealing PT-112’s immunogenic cell death (ICD) properties at the Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival.
Click here to access the abstract
Phosplatin Therapeutics To present translational research in hematological malignancies at the ASH 2017 Annual Meeting.
Click here to access the abstract
Phosplatin Therapeutics presents data from its Phase I study of PT-112, selected for an oral discussion session at the ASCO 2017 Annual Meeting.
Click here to access the abstract
Phosplatin therapeutics to present along with the Institute of cancer research montpellier at the AACR 2017 Annual meeting
Click here to access the abstract
Phosplatin Therapeutics announces launch of Phase I clinical trial